摘要
目的:探讨阿加曲班注射液联合依达拉奉治疗急性脑梗死(ACI)的疗效及对炎性因子指标的影响。方法:将180例ACI患者遵循随机的方法分为两组:研究组和对照组,各90例。在常规治疗的基础上,对照组应用依达拉奉注射液治疗,研究组联合应用阿加曲班注射液及依达拉奉注射液治疗。对临床疗效进行比较,对NIHSS评分、BI指数、血清hs-CRP、IL-6及TNF-α水平治疗前后的变化进行比较,观察治疗期间不良反应发生情况。结果:在治疗总有效率方面,研究组高于对照组(95.56%VS 85.56%,P<0.05)。NIHSS评分治疗后两组均低于治疗前,BI指数治疗后两组均高于治疗前(P<0.05);与对照组治疗后比较,研究组NIHSS评分治疗后降低,BI指数治疗后升高(P<0.05)。血清hs-CRP、IL-6及TNF-α水平两组治疗后均降低(P<0.05),与对照组治疗后比较,研究组炎症因子水平治疗后降低(P<0.05)。两组治疗期间均未见明显不良反应。结论:采用阿加曲班注射液与依达拉奉注射液联合治疗ACI效果确切,患者神经功能改善,日常生活能力提高,机体炎症反应得到控制,不良反应发生率低,值得临床推广。
Objective:To investigate the efficacy of argatroban injection combined with edaravone in the treatment of acute cerebral infarction(ACI)and its effect on inflammatory factors.Method:180 patients with ACI were randomly divided into two groups:study group and control group,with 90 cases in each group.On the basis of routine treatment,the control group was treated with edaravone injection,and the study group was treated with argatroban injection and edaravone injection.The clinical efficacy was compared,and the NIHSS score,Bi index,serum hs CRP,IL-6 and TNF were compared-αThe changes before and after treatment were compared,and the occurrence of adverse reactions during treatment was observed.Result:The total effective rate of the study group was higher than that of the control group(95.56%VS 85.56%,P<0.05).NIHSS score after treatment was lower than that before treatment,and Bi index after treatment was higher than that before treatment(P<0.05);Compared with the control group after treatment,the NIHSS score in the study group decreased and the Bi index increased after treatment(P<0.05).Serum hs CRP,IL-6 and TNF-αThe level of inflammatory factors in the study group decreased after treatment(P<0.05).There were no obvious adverse reactions in both groups during treatment.Conclusion:The combination of argatroban injection and edaravone injection is effective in the treatment of ACI.The neurological function of patients is improved,the ability of daily living is improved,the inflammatory reaction of the body is controlled,and the incidence of adverse reactions is low.It is worthy of clinical promotion.
作者
王娇
Wang Jiao(Department of Neurology,Tianjin Wuqing District People's Hospital,Tianjin 301700)
出处
《黑龙江医药》
CAS
2022年第3期572-575,共4页
Heilongjiang Medicine journal
关键词
阿加曲班
依达拉奉
急性脑梗死
疗效
炎症反应
Agatraban
Edaravone
Acute cerebral infarction
Curative effect
Inflammatory reaction
